Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942110 | 1.00 | LMNA (0.37) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15311996 | 1.00 | LMNA (0.37) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30461150 | 1.00 | LMNA (0.37) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4753902 | 0.88 | ALOX15 (0.38) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2337806 | 0.88 | ALDH1A1 (0.38) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30666800 | 0.88 | LMNA (0.38) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17460403 | 0.88 | LMNA (0.38) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10646190 | 0.88 | ALDH1A1 (0.38) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10440008 | 0.87 | LMNA (0.35) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2986680 | 0.85 | CYP2C19 (0.39) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951022-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2860175-B1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF | TACURION (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9598373-B2 | Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method | TACURION (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2657227-B1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20150141641-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | ASTELLAS PHARMA INC. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2860175-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF | Astellas Pharma Inc. (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8883792-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2657227-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| EP-1619185-B1 | 4,4-DIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-7807664-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLA PHARMA INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-7183271-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060122170-A1 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLA PHARMA INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1619185-A1 | 4,4-DIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT2A1, SULT1A1, SFPQ | LMNA 4114/4885CYP2C19 1539/4885CYP1A2 577/4885 |
| US-20150141641-A1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD | AVPR2, AVPR1A, AVPR1B | LMNA 2939/4885CYP2C19 1324/4885CYP1A2 1434/4885 |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | SLC5A1, SLC5A2, DPP4 | LMNA 4192/4885CYP2C19 2132/4885CYP1A2 3430/4885 |
| US-20060122170-A1 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | SLC5A1, SLC5A2, DPP4 | LMNA 4192/4885CYP2C19 2132/4885CYP1A2 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.